Introduction {#ss1}
============

A number of heterologous expression systems have been devised over the last decade for the production of clinically useful recombinant proteins, involving, in most cases, eukaryotic hosts competent in performing complex post‐translational modifications typical of mammalian proteins ([Dyck *et al*., 2003](#b1){ref-type="ref"}; [Ma *et al*., 2003](#b2){ref-type="ref"}; [Gerngross, 2004](#b3){ref-type="ref"}; [Wurm, 2004](#b4){ref-type="ref"}). Plant‐based expression platforms, in particular, offer unique advantages over traditional expression hosts in terms of cost efficiency, product safety, available expertise and facilities for culture and storage, and scalability easily adaptable to production needs ([Daniell *et al*., 2001](#b5){ref-type="ref"}; [Ma *et al*., 2003](#b2){ref-type="ref"}; [Twyman *et al*., 2003](#b6){ref-type="ref"}; [Streatfield, 2007](#b7){ref-type="ref"}). To date, several proteins of medical interest have been expressed successfully in plants, including a variety of antibodies, vaccine antigens, protein allergens, enzymes and enzyme inhibitors, coagulation factors, cytokines and hormones ([Hiatt *et al*., 1989](#b8){ref-type="ref"}; [Mason *et al*., 1992](#b9){ref-type="ref"}; [Ma *et al*., 1995](#b10){ref-type="ref"}, [2003](#b2){ref-type="ref"}, [2005a](#b12){ref-type="ref"}; [Ruggiero *et al*., 2000](#b11){ref-type="ref"}; [Kirk and Webb, 2005](#b13){ref-type="ref"}; [Twyman *et al*., 2005](#b14){ref-type="ref"}; [Floss *et al*., 2007](#b15){ref-type="ref"}; [Lienard *et al*., 2007](#b16){ref-type="ref"}).

A significant challenge in most systems is to optimize the yield and quality of the recombinant protein product. Significant progress has been achieved over the last 15 years in the optimization of transgene transcription and translation in plants ([Potenza *et al*., 2004](#b17){ref-type="ref"}; [Streatfield, 2007](#b7){ref-type="ref"}) and the elucidation and modulation of the complex protein post‐translational modifications characteristic of the plant cell machinery ([Gomord and Faye, 2004](#b18){ref-type="ref"}; [Faye *et al*., 2005](#b19){ref-type="ref"}). Despite these advances, ensuring satisfactory yield and quality of recombinant proteins often remains a difficult task. Unlike several more stable (and structurally less complex) pharmaceuticals, proteins present a natural tendency to structural heterogeneity, often giving a complex mixture of variants differing in their primary or tertiary structure ([Faye *et al*., 2005](#b19){ref-type="ref"}). This natural bias of proteins, which underlines important issues of product authenticity and heterogeneity, also emphasizes the need for a correct understanding of the various post‐translational steps of the whole protein synthesis‐recovery process, from the maturation and assembly of nascent protein backbones in transgenic host cells to the extraction and purification of the protein product after biomass harvesting.

Proteolytic degradation of recombinant proteins in plant systems {#ss2}
================================================================

One factor strongly influencing recombinant protein quality and yield is the relative inherent stability of polypeptide chains expressed in a heterologous environment ([Faye *et al*., 2005](#b19){ref-type="ref"}). Living cells are the theatre of numerous proteolytic processes, essential to ensure vital metabolic functions, but often a burden for the effective production of biologically active proteins ([Doran, 2006](#b20){ref-type="ref"}; [Goulet and Michaud, 2006](#b21){ref-type="ref"}). Proteolytic enzymes, or proteases, contribute to the overall control of metabolic and transduction pathways by directing the activation or hydrolysis of proteins implicated in key regulatory processes, or by contributing to the elimination of misfolded proteins and the selective recycling of amino acids from short‐lived proteins ([Vierstra, 2003](#b22){ref-type="ref"}; [Schaller, 2004](#b23){ref-type="ref"}). In plants, these enzymes also initiate the general recycling of proteins in senescing organs and the mobilization of amino acid constituents of seed or tuber storage proteins during germination ([Müntz, 2007](#b24){ref-type="ref"}). Hundreds of genes code for proteins involved in proteolytic processes in plants ([Rawlings *et al*., 2008](#b25){ref-type="ref"}), with, for instance, an estimate of 1900 genes in *Arabidopsis* directly or indirectly implicated in the hydrolysis of peptide bonds ([Schaller, 2004](#b23){ref-type="ref"}; [Smalle and Vierstra, 2004](#b26){ref-type="ref"}).

From a practical viewpoint, the ubiquitous nature of proteolytic processes ([Schaller, 2004](#b23){ref-type="ref"}) and the diversity of possible protease forms in the plant genome ([Beers *et al*., 2004](#b27){ref-type="ref"}) pose a significant challenge to the efficient production of several recombinant proteins. Although some proteins accumulate at high levels in plant systems, other proteins apparently undergo extensive hydrolysis, with a strong negative impact on the final yield despite easily detectable mRNA transcripts. Accumulation levels below 0.01% of total soluble protein (TSP) in plant tissues have been observed for several proteins of therapeutic value, including, for instance, human serum protein C, interferon β, erythropoietin and epidermal growth factor ([Daniell *et al*., 2001](#b5){ref-type="ref"}). Low accumulation rates of intact protein products have also been observed for other recombinant proteins of practical interest, including immunoglobulins, antibodies and enzyme inhibitors (e.g. [Stevens *et al*., 2000](#b28){ref-type="ref"}; [Sharp and Doran, 2001](#b29){ref-type="ref"}; [Ma *et al*., 2003](#b2){ref-type="ref"}; [Outchkourov *et al*., 2003](#b30){ref-type="ref"}; [Schillberg *et al*., 2005](#b31){ref-type="ref"}), again suggesting the key influence of proteolysis on the overall efficiency of plant‐based protein factories.

Proteases may affect the integrity of recombinant proteins in different ways, both *in planta* during protein expression and *ex planta* during extraction and subsequent downstream processing ([Michaud *et al*., 1998](#b32){ref-type="ref"}; [Rivard *et al*., 2006](#b33){ref-type="ref"}). Depending on the number of 'susceptible' cleavage sites accessible to endogenous proteases for peptide bond hydrolysis, the protein may undergo complete hydrolysis directly impacting on its final yield or partial trimming, altering the activity or homogeneity of the final protein product. Although interesting yields may be obtained in terms of net protein levels, the final product may show altered integrity, structural heterogeneity and/or deficient biological activity, potentially altering its value for commercialization ([Faye *et al*., 2005](#b19){ref-type="ref"}). Several strategies have been considered recently to minimize proteolysis in plant protein factories. This article summarizes these strategies, taking into account proteolysis observed *in planta* before harvesting, and unwanted proteolytic degradation observed *ex planta* during protein recovery from plant tissues and cells.

Stabilizing recombinant proteins *in planta* {#ss3}
============================================

In theory, the easiest way to minimize recombinant protein hydrolysis *in planta* is to use mutant lines deficient in protease(s) active against the protein of interest. Protease‐deficient strains of simple expression hosts, such as *Escherichia coli* ([Jiang *et al*., 2002](#b155){ref-type="ref"}; [Rozkov and Enfors, 2004](#b34){ref-type="ref"}) and yeasts ([Sreekrishna *et al*., 1997](#b35){ref-type="ref"}; [Cereghino and Cregg, 2000](#b36){ref-type="ref"}; [Macauley‐Patrick *et al*., 2005](#b37){ref-type="ref"}), were devised several years ago to minimize recombinant protein loss *in vivo*, and such strains are now available commercially and used routinely in most protein biochemistry laboratories. This approach, however, may not be applicable to complex, multicellular organisms such as higher plants, given the central role of proteolysis in growth and development ([Schaller, 2004](#b23){ref-type="ref"}), the expected diversity and variability of protease forms in plant cells and tissues ([Beers *et al*., 2004](#b27){ref-type="ref"}), and the large number of protease--protein interactions possibly taking place *in vivo*, which will depend on both the structural characteristics of each protein to be expressed and the metabolic status of each cell compartment or tissue targeted for protein deposition. At this stage, a case‐by‐case empirical assessment involving the testing of different expression strategies remains the most straightforward way to optimize the production yield and structural integrity of a given protein. Common strategies to overcome unwanted proteolysis *in planta* involve the targeting of transgene expression or protein accumulation to specific tissues or cellular organelles. Approaches involving the grafting of protein‐stabilizing fusion domains to recombinant proteins or the co‐expression of companion protease inhibitors interfering with endogenous proteases have also been proposed recently.

Tissue‐specific transgene expression {#ss4}
------------------------------------

For several reasons, the specific tissue or organ selected for recombinant protein production has a strong influence on the final yield and product quality. Cellular proteases, notably, differ from one tissue to another in terms of quantity and quality (or overall substrate specificity) ([Schaller, 2004](#b23){ref-type="ref"}), with a possible differential impact on the integrity of proteins. Historically, recombinant proteins in plants have often been expressed under the control of strong constitutive promoters, such as the cauliflower mosaic virus 35S promoter or the maize ubiquitin 1 promoter, but several tissue‐/organ‐specific (e.g. seed‐specific) promoters have been isolated and are now used to express transgenes in selected tissues and organs ([Potenza *et al*., 2004](#b17){ref-type="ref"}). In practice, an effective scheme for recombinant protein production should not only provide effective transcription of the transgene sequence, but also involve an accumulation site with low levels of overall proteolytic activity or with endogenous protease species showing no (or little) specific activity against accessible peptide bonds in the protein of interest.

To date, green leaves have been the destination of choice for several recombinant proteins, given their rapid growth rate, the possibility in some platforms to harvest leaf material more than once over the growing season, and the availability of numerous regulatory sequences well adapted to transgene expression in the leaf cell environment ([Daniell *et al*., 2001](#b5){ref-type="ref"}). However, the highly active metabolism of leaf tissues, which typically exhibit high protein synthesis and turnover rates, may represent a significant hurdle to protein accumulation *in vivo*. In particular, increased protease levels in senescing leaves ([Kato *et al*., 2004](#b39){ref-type="ref"}, [2005](#b40){ref-type="ref"}; [Lin and Wu, 2004](#b38){ref-type="ref"}; [Otegui *et al*., 2005](#b41){ref-type="ref"}; [Parrott *et al*., 2005](#b42){ref-type="ref"}) represent a potential drawback in leaf‐based production systems ([Stevens *et al*., 2000](#b28){ref-type="ref"}; [Birch‐Machin *et al*., 2004](#b43){ref-type="ref"}), both *in vivo* before protein recovery when senescence‐associated amino acid recycling is initiated, and *in vitro* during extraction once cellular proteases have been released into the extraction medium together with the protein(s) of interest. The abundance of poorly specific proteases and phenolic compounds in green tissues ([Michaud and Asselin, 1995](#b44){ref-type="ref"}) also leads to the problem of post‐harvest protein degradation and denaturation in leaves, which can make it necessary to process leaf biomass shortly after harvest, or to store this material at low temperatures until protein extraction ([Schillberg *et al*., 2005](#b31){ref-type="ref"}).

By contrast with leaf tissues, the seeds and storage organs of several crops appear, in general, to be well suited for the efficient deposition and post‐harvest storage of recombinant proteins ([Stoger *et al*., 2005](#b45){ref-type="ref"}). Proteins of clinical interest have been successfully expressed in seeds of several species, including major cereal crops (e.g. maize, rice, barley and wheat), soybean and safflower, under the control of either constitutive or seed‐specific promoters. Recombinant proteins in seeds often accumulate in storage organelles, mainly in protein bodies and protein storage vacuoles ([Streatfield *et al*., 2003](#b46){ref-type="ref"}; [Yang *et al*., 2005](#b47){ref-type="ref"}; [Drakakaki *et al*., 2006](#b48){ref-type="ref"}). The desiccated nature of mature seeds, together with the low abundance of active proteases in seed tissues during dormancy, prevent extensive proteolysis and promote long‐term stability of proteins *in planta* ([Fiedler and Conrad, 1995](#b49){ref-type="ref"}; [Stoger *et al*., 2000](#b50){ref-type="ref"}). In a similar manner, the tubers and storage roots of some species exhibit reduced metabolic activity, and may represent an interesting solution for recombinant protein storage. [Artsaenko *et al*. (1998](#b51){ref-type="ref"}), for instance, documented the long‐term stability of a single‐chain Fv antibody in potato tubers after storage for more than a year. From a technological viewpoint, storage organs also present anatomical features favourable to protein stability, such as the presence of protein and oil bodies in seeds, that may sequester proteins and minimize their exposure to proteases during extraction ([Stoger *et al*., 2005](#b45){ref-type="ref"}).

Organelle‐specific protein targeting {#ss5}
------------------------------------

Protein sequestration in, or targeting to, specific cell compartments has also been readily recognized as a key factor determining the overall stability and yield of recombinant proteins *in planta* ([Wandelt *et al*., 1992](#b52){ref-type="ref"}; [Schouten *et al*., 1996](#b53){ref-type="ref"}; [Gomord *et al*., 1997](#b54){ref-type="ref"}). Organelles play specific, complementary functions in the cell and thus harbour their own metabolic machinery, including a protease complement well adapted to their particular enzymatic and physicochemical environment ([Callis, 1995](#b55){ref-type="ref"}). Not surprisingly, the targeting of foreign proteins to different organelles using appropriate peptide signals has a strong impact on their accumulation rate ([Table 1](#t1){ref-type="table"}). In biochemical terms, the stability of a given protein *in vivo* will depend on the relative steric accessibility of peptides or peptide strings on the protein chain susceptible to the proteases present. In practice, the choice of a suitable cellular destination will also depend on the structural characteristics of the recombinant protein, which will often dictate specific co‐ or post‐translational modifications essential for adequate activity, stability and/or homogeneity ([Faye *et al*., 2005](#b19){ref-type="ref"}).

###### 

Impact of subcellular targeting on recombinant protein yield in transgenic plant systems -- selected examples

  Protein                                        Transformed species                          Plant organ   Yield[\*](#t1n1){ref-type="fn"}   Reference                               
  ---------------------------------------------- -------------------------------------------- ------------- --------------------------------- ----------- -------- -------- ---- ---- ------------------------------------------------------
  **Antibodies**                                                                                                                                                                      
  ScFv anti‐cutinase                             *Nicotiana tabacum*                          Leaf          0                                 100                  1                  [Schouten *et al*. (1996](#b53){ref-type="ref"})
  ScFv anti‐oxazolone                            *N. tabacum*                                 Leaf                                            10--20               1                  [Fielder *et al*. (1997)](#b153){ref-type="ref"}
  Seed                                                                                        5, 22                                           1                                       
  ScFv anti‐oxazolone                            *Solanum tuberosum*                          Tuber                                           1                    1                  [Artsaenko *et al*. (1998](#b51){ref-type="ref"})
  ScFv anti‐dihydroflavonol 4‐reductase          *Petunia hybrida*\*\*                        Petal         1                                 2, 30                                   [De Jaeger *et al*. (1999](#b62){ref-type="ref"})
  Leaf                                           1                                            20, 60                                                                                  
  BiscFv 2429                                    *N. tabacum*                                 BY‐2 cells    Traces                            10                   1                  [Fischer *et al*. (1999)](#b154){ref-type="ref"}
  FAb MAK33                                      *Arabidopsis thaliana*                       Leaf/seed                                       1                    1                  [Peeters *et al*. (2001)](#b157){ref-type="ref"}
  scFv anti‐carcinoembryonic                     *N. tabacum*                                 Leaf                                            25                   1                  [Stoger *et al*. (2002)](#b78){ref-type="ref"}
  Ab anti‐carcinoembryonic                       *N. tabacum*\*\*                             Leaf                                            2--6                 1                  [Vaquero *et al*. (2002)](#b158){ref-type="ref"}
  Ab 14D9 κ chain                                *N. tabacum*                                 Leaf                                            8                    1                  [Petruccelli *et al*. (2006)](#b159){ref-type="ref"}
  Ab 14D9 γ chain                                                                                                                             4                    1                  
  **Vaccines**                                                                                                                                                                        
  *Escherichia coli* heat‐labile enterotoxin B   Zea mays                                     Seed          1                                 100         20 000   3300     7    21   [Streatfield *et al*. (2003)](#b46){ref-type="ref"}
  Hepatitis B surface antigen                    *N. tabacum*                                 BY‐2 cells    1                                 1.4                  1.8                [Sojikul *et al*. (2003](#b89){ref-type="ref"})
  Japanese cedar pollen allergens                *Oryza sativa*                               Seed          0                                 4--6                 1                  [Takagi *et al*. (2005)](#b160){ref-type="ref"}
  **Medical proteins**                                                                                                                                                                
  Human epidermal growth factor                  *N. tabacum*                                 Leaf          1                                                      10 000             [Wirth *et al*. (2004)](#b91){ref-type="ref"}
  Human growth hormone                           *N. benthamiana* [†](#t1n2){ref-type="fn"}   Leaf          1                                                      1000     10        [Gils *et al*. (2005](#b56){ref-type="ref"})
  **Agronomic/industrial proteins**                                                                                                                                                   
  Vicilin                                        *N. tabacum*                                 Leaf                                            100                  1                  [Wandelt *et al*. (1992)](#b52){ref-type="ref"}
  *Medicago sativa*                              Leaf                                                       20                                            1                           
  Equistatin                                     *S. tuberosum*                               Leaf          1                                 5                                       [Outchkourov *et al*. (2003)](#b30){ref-type="ref"}
  Silk‐like protein                              *A. thaliana*                                Leaf          1                                 13          0        5                  [Yang *et al*. (2005)](#b47){ref-type="ref"}
  Seed                                           1                                            7.8           5.4                               0                                       

Relative yield, compared with the yield in 'control' compartment (value of unity).

Transient expression.

Eventual metabolic interference effects on the host plant actively expressing the recombinant protein should also be assessed, given the possible onset of organelle‐dependent effects of biologically active proteins *in planta*. Cytosolic or apoplastic accumulation of the human growth factor, for instance, had toxic effects in leaves of *Nicotiana benthamiana*, whereas, in contrast, no negative effects were observed for the same protein targeted to the chloroplast ([Gils *et al*., 2005](#b56){ref-type="ref"}). Likewise, the bovine protease inhibitor aprotinin was accumulated at high specific levels when retained in the endoplasmic reticulum (ER) of potato leaf cells, but this positive effect of ER retention was counterbalanced by a general decrease in total protein content in leaves, presumably as a result of the exogenous inhibitor affecting key steps of protein biosynthesis *in vivo* ([Badri, 2006](#b57){ref-type="ref"}). Considering the complexity of protein maturation processes in plant cells and the often unpredictable nature of pleiotropic effects in transgenic host plants, the most appropriate way to select a suitable cellular destination at this stage involves the empirical testing of different possible destinations, taking into account current knowledge on the protein being expressed and on the physicochemical and enzymatic microenvironment of the different organelles available for protein accumulation. Several subcellular compartments have been considered as possible destinations for recombinant proteins in plant cells, including the cytosol, the chloroplast and different subcompartments of the cell secretory pathway ([Ma *et al*., 2003](#b2){ref-type="ref"}; [Daniell, 2006](#b58){ref-type="ref"}; [Goulet and Michaud, 2006](#b21){ref-type="ref"}).

### Retention in the cytosol {#ss6}

In practice, the absence of a targeting signal in the transgene sequence prevents migration of the recombinant protein out of the cytosol following mRNA translation ([Figure 1](#f1){ref-type="fig"}). Recombinant proteins retained in the cytosol are usually detected at very low levels despite good transgene transcription rates, giving, in several cases, accumulation rates below 0.1% of TSP ([Conrad and Fiedler, 1998](#b59){ref-type="ref"}). Cytosolic targeting of the tomato mosaic virus antibody 'rAb29' in tobacco leaf cells, for instance, resulted in very weak accumulation rates, whereas the same transgene including a signal peptide for extracellular secretion produced easily detectable amounts of this protein ([Schillberg *et al*., 1999](#b60){ref-type="ref"}). Similarly, retaining human growth hormone in the cytosol of *N. benthamiana* leaf cells led to protein levels of about 0.01% of TSP, in contrast with concentrations reaching 10% of TSP for the same protein targeted to the apoplast ([Gils *et al*., 2005](#b56){ref-type="ref"}). Several factors may explain the limited suitability of the cytosol as a destination for recombinant proteins: (i) the negative redox potential of the cytosolic milieu, unfavourable to the correct folding of proteins with disulphide bonds ([Goulet and Michaud, 2006](#b21){ref-type="ref"}); (ii) the absence of important co‐ and post‐translational modification processes, such as glycosylation, which may have a positive impact on the folding, assembly and/or structural stability of several nascent and mature proteins ([Faye *et al*., 2005](#b19){ref-type="ref"}); and (iii) the effective housekeeping activity of the ubiquitin--proteasome proteolytic pathway in this cellular compartment ([Vierstra, 1996](#b61){ref-type="ref"}, [[2]{.smallcaps}003](#b22){ref-type="ref"}), involved notably in the recognition and degradation of incorrectly folded proteins. Although some recombinant proteins remain stable in the cytosol (e.g. [Michaud *et al*., 1998](#b32){ref-type="ref"}; [De Jaeger *et al*., 1999](#b62){ref-type="ref"}; [Rajabi‐Memari *et al*., 2006](#b63){ref-type="ref"}; [Marusic *et al*., 2007](#b64){ref-type="ref"}), alternative destinations, such as the chloroplast, the ER or the apoplast, appear to be more appropriate for most proteins.

![Subcellular targeting of recombinant proteins in plant cells. Recombinant proteins bearing an N‐terminal signal peptide (SP) in their primary sequence enter the cell secretory pathway via the endoplasmic reticulum (ER), and then travel through the Golgi system to be secreted in the apoplast (default pathway) or directed to the vacuole if a vacuolar sorting determinant (VSD) is present in the protein sequence. Proteins secreted into the ER can also be retained in this compartment by the grafting of an ER retention signal -- the KDEL (or HDEL) tetrapeptide motif -- at the C‐terminus. Proteins with no signal peptide accumulate in the cytosol (default location) or migrate to specific organelles when an appropriate peptide signal is included in the transgene sequence. Peptide signals used recently in transgenic plant platforms include plastid (e.g. chloroplast) transit peptides (PTP), nuclear localization signals (NLS) and the tripeptide peroxisome target sequence serine‐lysine‐leucine (SKL).](PBI-6-633-g001){#f1}

### Retention in the ER {#ss7}

Targeting to the cell secretory pathway, in particular, has been proposed to improve the stability and yield of several proteins ([Ma *et al*., 2003](#b2){ref-type="ref"}; [Yoshida *et al*., 2004](#b65){ref-type="ref"}; [Vitale and Pedrazzini, 2005](#b66){ref-type="ref"}). In practice, the addition of an N‐terminal signal peptide sequence to the protein‐encoding transgene triggers a co‐translational transfer of the nascent protein to the endomembrane system ([Chrispeels and Faye, 1996](#b67){ref-type="ref"}) ([Figure 1](#f1){ref-type="fig"}). Proteins bearing a signal peptide for cellular secretion first enter the ER via the ER protein translocation channel ([Galili *et al*., 1998](#b68){ref-type="ref"}), and then migrate through this compartment and the Golgi apparatus until reaching the extracellular medium (default pathway) or the vacuole, if a vacuolar sorting signal is found in the primary sequence. Recombinant proteins entering the ER may also be retained in this compartment by simple apposition of the tetrapeptide ER retention signal (K/H)DEL ([Michaud *et al*., 1998](#b32){ref-type="ref"}) or grafting of a γ‐zein proline‐rich domain ([Mainieri *et al*., 2004](#b69){ref-type="ref"}) at the C‐terminus. The (K/H)DEL motif is a common ER retrieval signal in eukaryotes, believed to redirect tagged proteins to the ER after their recognition by a (K/H)DEL receptor complex in the Golgi apparatus ([Lee *et al*., 1993](#b70){ref-type="ref"}; [Pagny *et al*., 2000](#b71){ref-type="ref"}). In contrast with most reticuloplasmins, cereal prolamins accumulate in the ER of seed cells without the involvement of the (K/H)DEL motif, forming high‐density protein bodies by a sequence‐specific sorting mechanism yet to be elucidated ([Vitale and Pedrazzini, 2005](#b66){ref-type="ref"}). In practice, the retention of zein (and other prolamins) in the ER, and the concomitant formation of protein bodies, may be easily reproduced in both storage and vegetative tissues of transgenic plants ([Geli *et al*., 1994](#b72){ref-type="ref"}; [Coleman *et al*., 1996](#b73){ref-type="ref"}), which makes this system potentially useful for the high‐level accumulation of recombinant proteins *in planta* and their easy recovery in crude extract preparations by gradient centrifugation procedures ([Torrent *et al*., 2006a](#b74){ref-type="ref"}, [b](#b75){ref-type="ref"}).

Numerous studies have been published illustrating the positive impact of retaining clinically or industrially useful proteins in the ER compartment of plant cells, using, in most cases, a (K/H)DEL retention signal ([Ma *et al*., 2003](#b2){ref-type="ref"}). The ER, which constitutes a natural reservoir for some storage proteins in seed cells ([Shewry and Halford, 2002](#b76){ref-type="ref"}), can physically accommodate high levels of recombinant protein product *in planta* ([Wandelt *et al*., 1992](#b52){ref-type="ref"}). At the biochemical level, the low abundance of proteolytic enzymes and the presence of molecular chaperones in the ER, together with an oxidizing status favouring disulphide bond formation, make this organelle a suitable destination for several proteins susceptible to rapid turnover or showing a complex folding pathway ([Nuttall *et al*., 2002](#b77){ref-type="ref"}; [Faye *et al*., 2005](#b19){ref-type="ref"}). Several reports have documented the positive impact of ER retention on the production of recombinant antibodies in terms of protein stability, quality or yield ([Schouten *et al*., 1996](#b53){ref-type="ref"}; [Conrad and Fiedler, 1998](#b59){ref-type="ref"}; [Stoger *et al*., 2002](#b78){ref-type="ref"}; [Gomord *et al*., 2004](#b79){ref-type="ref"}). Similar tendencies have been observed for several other proteins of medical or industrial interest, including, as recent examples, human interleukin‐4 ([Ma *et al*., 2005b](#b80){ref-type="ref"}), the SARS coronavirus S protein antigen ([Pogrebnyak *et al*., 2005](#b81){ref-type="ref"}), the synthetic silk‐like protein DR1B ([Yang *et al*., 2005](#b47){ref-type="ref"}) and a recombinant phytase from *Aspergillus niger* ([Peng *et al*., 2006](#b156){ref-type="ref"}).

Despite these promising developments, the ER cannot be considered as a suitable destination for all proteins. To be stable or active, a number of clinically useful proteins require late post‐translational modifications, such as the formation of complex glycans, the addition of a lipid moiety or the proteolytic removal of a propeptide sequence, which may occur downstream of the ER along the secretory pathway, notably in the Golgi, vacuole or apoplast ([Gomord and Faye, 2004](#b18){ref-type="ref"}; [Faye *et al*., 2005](#b19){ref-type="ref"}). Other proteins may exhibit an altered integrity or structural heterogeneity in the ER, as a result of unintended proteolytic processing by ER‐resident proteases ([Faye *et al*., 2005](#b19){ref-type="ref"}). The ER lumen is generally considered to be a mild environment for labile, e.g. immature, proteins, but proteolytic processing events altering the structure of secreted proteins have been observed in this compartment ([Bass *et al*., 2000](#b82){ref-type="ref"}; [Schmitz and Herzog, 2004](#b83){ref-type="ref"}). For instance, the bovine plasma protein aprotinin expressed in leaves of transgenic potato showed structural heterogeneity when accumulated in the ER, presumably as a result of the sequential removal of specific amino acids at the N‐ and C‐termini by endogenous peptidases ([Badri *et al*., 2005](#b84){ref-type="ref"}). A potential solution to prevent unintended proteolytic processing in the ER, or later along the secretory pathway ([Sharp and Doran, 2001](#b29){ref-type="ref"}), is to identify and mutate susceptible amino acid sites by site‐directed mutagenesis, as suggested by [Outchkourov *et al*. (2003](#b30){ref-type="ref"}) for the sea anemone protein equistatin, processed to several truncated forms in the secretory pathway of transgenic potato leaf cells by arginine/lysine‐ and asparagine‐specific cysteine proteases.

### Targeting to the apoplast {#ss8}

Simply targeting the protein to an alternative compartment, even downstream in the cell secretory pathway, may also help to prevent unintended processing. For instance, recombinant bovine aprotinin targeted to the apoplast of potato leaf cells can be detected as a homogeneous, unprocessed form, similar in size to the native protein purified from bovine pancreas ([Badri *et al*., 2008](#b85){ref-type="ref"}), in contrast with the proteolysis‐related heterogeneity mentioned above for the same protein retained in the ER. The extracellular medium typically exhibits a high proteolytic content ([Callis, 1995](#b55){ref-type="ref"}; [Hellwig *et al*., 2004](#b86){ref-type="ref"}; [Schiermeyer *et al*., 2005](#b87){ref-type="ref"}), but several recombinant proteins tagged for extracellular secretion have been produced successfully in plant or plant cell platforms over the last few years ([Gaume *et al*., 2003](#b88){ref-type="ref"}; [Sojikul *et al*., 2003](#b89){ref-type="ref"}; [Streatfield *et al*., 2003](#b46){ref-type="ref"}; [Wirth *et al*., 2004](#b91){ref-type="ref"}; [Hellwig *et al*., 2004](#b86){ref-type="ref"}; [Komarnytsky *et al*., 2004](#b90){ref-type="ref"}; [Gils *et al*., 2005](#b56){ref-type="ref"}; [Yang *et al*., 2005](#b47){ref-type="ref"}). Proteolytic processing in the extracellular medium may even represent an advantage for the correct maturation of certain proteins, as illustrated recently with the dust mite allergenic protein Der p 1, processed to its mature, active form in the culture medium of transgenic BY‐2 tobacco cells naturally secreting proteases with hydrolytic activity against the propeptide sequence of this protein ([Lienard *et al*., 2007](#b16){ref-type="ref"}).

### Targeting to the vacuole {#ss9}

Similar to the apoplastic medium, the vacuole represents a suitable accumulation site for several recombinant proteins, especially for production platforms relying on seed tissues ([Stoger *et al*., 2005](#b45){ref-type="ref"}). The vacuole plays several important roles *in planta*, including the control of cell turgor, the turnover of macromolecules, the sequestration of toxic secondary metabolites and the storage of high‐energy compounds in seeds or vegetative storage tissues ([Marty, 1999](#b92){ref-type="ref"}). Recent evidence in the literature has suggested the occurrence of two distinct types of vacuole in plant cells: lytic (or vegetative) vacuoles, which present an acidic environment rich in hydrolytic enzymes; and protein storage vacuoles, which show a slightly acidic or neutral pH well adapted to protein storage ([Robinson *et al*., 2005](#b93){ref-type="ref"}). Targeting to the vacuole, although not yet fully understood, is determined by small stretches of amino acids within the protein primary sequence acting as sorting signals to direct the maturing protein towards the vacuole ([Neuhaus and Rogers, 1998](#b94){ref-type="ref"}; [Mackenzie, 2005](#b95){ref-type="ref"}; [Vitale and Hinz, 2005](#b96){ref-type="ref"}). In general, lytic vacuoles are not considered as a suitable destination for recombinant proteins *in planta*, owing to their high proteolytic content ([Goulet and Michaud, 2006](#b21){ref-type="ref"}). By contrast, protein storage vacuoles present a milder environment compatible with protein accumulation ([Stoger *et al*., 2005](#b45){ref-type="ref"}), especially in seeds, where they are most abundant ([Müntz, 1998](#b98){ref-type="ref"}; [Park *et al*., 2004](#b99){ref-type="ref"}).

Good accumulation levels have been reported for a number of recombinant proteins targeted to the vacuole ([Table 1](#t1){ref-type="table"}), including, for instance, the synthetic analogue of spider dragline silk protein DP1B ([Yang *et al*., 2005](#b47){ref-type="ref"}), the heat‐labile enterotoxin B from *E. coli* ([Streatfield *et al*., 2003](#b46){ref-type="ref"}), the toxic biotin‐binding proteins avidin and streptavidin ([Murray *et al*., 2002](#b100){ref-type="ref"}) and a thermostable β‐glucanase of bacterial origin ([Horvath *et al*., 2000](#b101){ref-type="ref"}). In practice, correct *in situ* localization of recombinant proteins bearing a sorting sequence for vacuolar targeting should be undertaken on a systematic basis, considering the species‐ or tissue‐dependent functionality of some sorting signals ([Vitale and Hinz, 2005](#b96){ref-type="ref"}). A good example of this phenomenon has been provided for a fungal phytase expressed in rice, which was readily detected in the apoplastic environment of leaf tissues, but retained in ER protein bodies and protein storage vacuoles in the seed endosperm ([Drakakaki *et al*., 2006](#b48){ref-type="ref"}). As illustrated with the silk‐like protein DP1B expressed in *Arabidopsis* ([Yang *et al*., 2005](#b47){ref-type="ref"}), the impact of vacuolar targeting on the stability and yield of recombinant proteins is also tissue dependent. Although this protein was found at levels reaching 8% of TSP in seed storage vacuoles, no detectable levels of the same protein could be observed in leaf cell vacuoles. In a similar manner, targeting DP1B to the apoplast provided good yields in leaves, but poor yields in seeds ([Yang *et al*., 2005](#b47){ref-type="ref"}), again stressing the need for an empirical case‐by‐case assessment of different tissue and cellular destinations for each protein expressed.

### Targeting to the chloroplast {#ss10}

The chloroplast, peroxisome and nucleus have been proposed as other cellular destinations for protein production in plant platforms ([Daniell *et al*., 2002](#b102){ref-type="ref"}; [Hyunjong *et al*., 2006](#b103){ref-type="ref"}). In practice, recombinant proteins may be sent to these organelles by the inclusion of an appropriate targeting peptide (or localization signal) in the transgene sequence ([Figure 1](#f1){ref-type="fig"}). For instance, the heat‐labile toxin Lt‐B from enterotoxicogenic *E. coli* exhibited increased levels in corn grains when diverted from the cytosol to the nucleus by the addition of a nuclear localization signal from the simian virus 40 large T‐antigen in the C‐terminal position ([Streatfield *et al*., 2003](#b46){ref-type="ref"}). In a similar manner, a fungal xylanase useful in environment‐related technologies showed high accumulation levels in *Arabidopsis* leaf tissues when sent to chloroplasts using the ribulose‐1,5‐bisphosphate carboxylase/oxygenase (rubisco) activase transit peptide, or sent to peroxisomes using the tripeptide targeting motif SKL (serine‐lysine‐leucine) grafted at the C‐terminus ([Hyunjong *et al*., 2006](#b103){ref-type="ref"}). Another example was the improved production of human growth hormone in *N. benthamiana* leaf cells when transferred from the cytosol to the chloroplast using the chloroplast transit peptide of rubisco small subunit ([Gils *et al*., 2005](#b56){ref-type="ref"}).

Efficient procedures have also been devised to insert transgenes in the chloroplast genome, and then to regenerate transplastomic plant lines accumulating high levels of recombinant protein directly in the chloroplast stroma ([Daniell *et al*., 2001](#b5){ref-type="ref"}; [Maliga, 2002](#b104){ref-type="ref"}). Chloroplast transformation offers several advantages over nuclear transformation, including uniform transgene expression rates, multiple copies of the transgene in each cell, co‐expression of multiple genes from the same construct, minimal gene silencing and minimal transgene escape in the environment owing to the maternal inheritance of chloroplast DNA in several species ([Daniell *et al*., 2002](#b102){ref-type="ref"}). The chloroplast stroma supports protein post‐translational modifications, such as multimerization and disulphide bridge formation ([Daniell, 2006](#b58){ref-type="ref"}), making it a suitable environment for the expression of proteins not relying on complex modifications, such as glycosylation, typical of the cell secretory pathway. Several transplastomic plant lines have been engineered over the last 10 years for recombinant protein expression, providing very high yields for a number of useful proteins of prokaryotic and eukaryotic origin, including somatotropin, serum albumin, anthrax protective antigen, cholera toxin B subunit and tetanus toxin fragment C ([Daniell *et al*., 2001](#b5){ref-type="ref"}, [2005](#b105){ref-type="ref"}; [Tregoning *et al*., 2003](#b106){ref-type="ref"}).

However, a number of endogenous proteases are present in the chloroplast ([Adam and Clarke, 2002](#b107){ref-type="ref"}), which can impair the overall stability and accumulation of recombinant proteins. An interesting example has been provided for the rotavirus VP6 protein, which showed high accumulation rates in chloroplasts of young tobacco leaves, but negligible rates in older leaves, despite comparable levels of mRNA transcripts ([Birch‐Machin *et al*., 2004](#b43){ref-type="ref"}). A similar decline in older tissues was observed for a fungal xylanase ([Hyunjong *et al*., 2006](#b103){ref-type="ref"}) and for the insecticidal Bt toxin Cry2Aa2 ([De Cosa *et al*., 2001](#b108){ref-type="ref"}), again stressing the importance of a careful assessment of the stability of each recombinant protein in different physiological or environmental contexts. Recombinant protein degradation by chloroplast proteases might appear, however, to be a non‐relevant issue in terms of net production yields for some proteins expressed at very high levels ([Daniell, 2006](#b58){ref-type="ref"}). The proteolysis‐labile protein human serum albumin, for instance, was found at levels reaching 11% of TSP in transplastomic tobacco lines developed using chloroplast untranslated regions in gene constructs, in sharp contrast with levels below 0.02% of TSP in lines developed using the commonly employed Shine--Delgarno regulatory sequence ([Fernandez‐San Millan *et al*., 2003](#b109){ref-type="ref"}). This dramatic increase, probably the result of an increased expression rate of the transgene, was also associated with the formation of large inclusion bodies *in vivo* ([Fernandez‐San Millan *et al*., 2003](#b109){ref-type="ref"}), which presumably sequestered the recombinant protein and prevented its hydrolysis*in planta*, as described earlier for a number of proteins expressed in heterologous environments ([Enfors, 1992](#b110){ref-type="ref"}).

Stabilizing fusion partners {#ss11}
---------------------------

Together with strategies based on tissue‐specific transgene expression or organelle‐specific protein targeting, protein engineering approaches involving site‐directed mutagenesis and/or protein domain grafting have been proposed to prevent recombinant protein hydrolysis *in planta*. Site‐directed mutagenesis may prove to be useful, in particular, in improving the intrinsic stability of labile proteins in plant cells, as proposed previously for recombinant proteins expressed in microbial systems ([Rozkov and Enfors, 2004](#b34){ref-type="ref"}; [Macauley‐Patrick *et al*., 2005](#b37){ref-type="ref"}). Any recombinant protein, depending on its structural characteristics, potentially includes protease‐susceptible amino acid sites sterically accessible to endogenous proteases in the transgenic host organism. In theory, the identification of such susceptible sites in the polypeptide chain, together with a correct knowledge of the host proteolytic machinery, can provide useful information for the design of protein variants with improved stability *in vivo* ([Rozkov *et al*., 2000](#b111){ref-type="ref"}). To our knowledge, this approach has not yet been applied to recombinant proteins expressed in plants, but the characterization of specific proteolytic events implicating recombinant proteins in transgenic plants (e.g. [Outchkourov *et al*., 2003](#b30){ref-type="ref"}; [Badri, 2006](#b57){ref-type="ref"}) should provide, in forthcoming years, a workable framework for the rational engineering of protein variants with improved resistance to plant proteases. The design of structurally stabilized, thermostable protein variants integrating one or several 'consensus' (conserved) amino acids ([Lehmann *et al*., 2002](#b112){ref-type="ref"}) may also prove to be interesting in the future, considering the strong positive correlation between the improved thermostability of such mutant proteins and their resistance to proteolysis ([Amin *et al*., 2004](#b113){ref-type="ref"}).

When structural constraints in the protein do not allow for an alteration of protease‐susceptible sites, or when a restrictive regulatory framework for therapeutic proteins dictates maximal identity between the recombinant protein and its original counterpart, expression of the protein attached to a protein‐stabilizing fusion partner may prove to be useful to enhance its stability and/or folding, whilst keeping intact its original primary structure. Early studies with staphylococcal protein A and streptococcal albumin‐binding protein demonstrated the potential of fusion partners as promoting agents for recombinant protein accumulation *in vivo* ([Nygren *et al*., 1994](#b114){ref-type="ref"}; [Stahl *et al*., 1997](#b115){ref-type="ref"}). In plants, several studies have been published describing the positive impact of protein fusion partners on the accumulation of recombinant proteins. Examples have been provided for the marker proteins β‐glucuronidase and luciferase and, more recently, for the cholera toxin B subunit, which were accumulated at higher rates in transgenic potato or tobacco leaves when the regulatory protein ubiquitin was fused and transiently present at the N‐terminus ([Garbino *et al*., 1995](#b116){ref-type="ref"}; [Hondred *et al*., 1999](#b117){ref-type="ref"}; [Mishra *et al*., 2006](#b118){ref-type="ref"}). More recently, the human immunodeficiency virus (HIV) p24 core antigen expressed in tobacco leaves showed an accumulation level increased by more than 10‐fold when heavy chains of a human immunoglobulin A were fused at the C‐terminus ([Obregon *et al*., 2006](#b119){ref-type="ref"}). In a similar manner, the accumulation rates of spider silk proteins, single‐chain antibody fragments, gp130 polypeptides and mammalian interleukins in transgenic tobacco lines were significantly improved when elastin‐like polypeptides, including repeats of the elastin motif VPGXG (valine‐proline‐glycine‐Xaa‐glycine), were fused at the C‐terminus ([Scheller *et al*., 2004](#b120){ref-type="ref"}, [2006](#b121){ref-type="ref"}; [Lin *et al*., 2006](#b122){ref-type="ref"}; [Patel *et al*., 2007](#b123){ref-type="ref"}). Although work is still required to devise efficient procedures for the proteolytic removal of fusion partners and to understand the mechanisms by which the different fusion partners exert their stabilizing effect, these observations clearly suggest the potential of fusion protein technologies for the improvement of recombinant protein yields in plants.

Companion protease inhibitors {#ss12}
-----------------------------

Another strategy proposed recently to increase recombinant protein production *in planta* involves the use of transgenic hosts with reduced proteolytic capacities. In theory, protease processes affecting recombinant protein accumulation could be contained using antisense or RNA silencing strategies implemented in transgenic host plants ([Watson *et al*., 2005](#b124){ref-type="ref"}). Alternatively, recombinant protease inhibitors active against specific endogenous proteases could prove functional to modulate proteolytic activities *in situ* ([Faye *et al*., 2005](#b19){ref-type="ref"}). Recent evidence in the literature has suggested that the ectopic expression of protease inhibitors may have a positive impact on protein levels in leaves, with negligible effects on growth and development. The broad‐spectrum inhibitor tomato cathepsin D inhibitor (CDI), for instance, has been shown to yield increased TSP levels (by 20%--35%) in leaves of transgenic potato lines accumulating this inhibitor in the cytosolic compartment ([Michaud *et al*., 2005](#b125){ref-type="ref"}). Likewise, the rice cysteine protease inhibitor oryzacystatin I led to total protein levels higher than expected in tobacco leaf tissues expressing this inhibitor in the cytosol ([van der Vyver *et al*., 2003](#b126){ref-type="ref"}). The design of transgenic plant lines deficient in specific protease activities could now represent a challenging but worthwhile task, which could provide mild cellular environments tailored for the expression and accumulation of fragile proteins. A convincing demonstration supporting the potential of this approach was provided by [Komarnytsky *et al*. (2006](#b127){ref-type="ref"}), who successfully stabilized recombinant antibodies secreted by the roots of transgenic tobacco plants also expressing (and co‐secreting) a Bowman--Birk trypsin inhibitor from soybean.

Stabilizing recombinant proteins *ex planta* {#ss13}
============================================

Together with strategies aimed at preserving the integrity of recombinant proteins *in planta*, basic strategies have been devised over the last 10 years to protect recombinant proteins *ex planta*, at the time of extraction from plant tissues. While the avoidance of unwanted proteolysis *in planta* is essential to provide sufficient protein levels before harvesting, proteolysis control *ex planta* is essential to prevent protein loss in crude preparations. Protein extraction is often considered as a simple preliminary step for subsequent purification procedures, but it has a dramatic influence on the overall stability and quality of extracted proteins, and hence on the nature and abundance of proteins available for subsequent analysis, enrichment and purification ([Michaud and Asselin, 1995](#b44){ref-type="ref"}). Simple basic precautions may be taken in the laboratory to prevent excessive proteolysis and to preserve recombinant protein integrity in plant samples and protein extracts ([Michaud, 1998](#b128){ref-type="ref"}). Molecular and cellular approaches have also been proposed in recent years to minimize degradation *ex planta*, relying on the co‐expression of protein‐stabilizing protease inhibitors or the continuous secretion of recombinant protein products.

Basic precautions during protein extraction {#ss14}
-------------------------------------------

From a practical viewpoint, plant cells are often seen as a 'recalcitrant' source of material for protein extraction, owing to their particular architecture and content ([Saravanan and Rose, 2004](#b129){ref-type="ref"}; [Carpentier *et al*., 2005](#b130){ref-type="ref"}). Compared with animal or microbial cells, plant cells from metabolically active tissues typically show a low protein content, and the vacuole(s), which account(s) for most of the cell volume, contain(s) highly reactive compounds potentially deleterious to proteins ([Michaud and Asselin, 1995](#b44){ref-type="ref"}). During extraction, at least some protein loss is to be expected, given the occurrence of poorly soluble material interacting non‐specifically with proteins in crude preparations, and the systematic release of protein denaturing agents, including phenolics and proteases, after cell disruption ([Menkhaus *et al*., 2004](#b131){ref-type="ref"}; [Saravanan and Rose, 2004](#b129){ref-type="ref"}). Although the onset of protein--protease interactions specific to each protein and expression platform will generally dictate the empirical development of adapted protection strategies during protein recovery, general guidelines have been proposed over the years to prevent protein loss in plant biomass and protein extracts ([Jervis and Pierpoint, 1989](#b132){ref-type="ref"}; [Michaud and Asselin, 1995](#b44){ref-type="ref"}; [Michaud, 1998](#b128){ref-type="ref"}; [Menkhaus *et al*., 2004](#b131){ref-type="ref"}; [Schillberg *et al*., 2005](#b31){ref-type="ref"}). In summary, these guidelines recommend: (i) the processing of biomass shortly after harvest for plant material retrieved from metabolically active tissues; and (ii) the adoption of laboratory practices preventing or at least minimizing protein loss and denaturation in crude extracts, including the processing of sample tissues at low temperatures, the addition of chelators and phenolic‐neutralizing compounds in the extraction buffer, the use of low‐molecular‐weight protease inhibitors active against the host plant endogenous proteases and the use of pH conditions unfavourable to proteolytic activity in crude extracts ([Michaud and Asselin, 1995](#b44){ref-type="ref"}). Protein extraction in acidic conditions, notably, may provide a simple method of preventing unwanted degradation of proteins extracted from several plant tissues, whilst also helping to avoid contamination of crude preparations with proteolytic fragments of larger proteins when low‐molecular‐weight proteins are to be isolated ([Zhang *et al*., 2006](#b133){ref-type="ref"}). For instance, studies have illustrated the usefulness of trifluoroacetic acid for the effective isolation and enrichment of bioactive polypeptides from different sources in stable and active forms ([Pearce *et al*., 2001](#b134){ref-type="ref"}; [Huffaker *et al*., 2006](#b135){ref-type="ref"}; [Yamaguchi *et al*., 2006](#b136){ref-type="ref"}).

Protein‐stabilizing protease inhibitors {#ss15}
---------------------------------------

At the laboratory scale, protease inhibitors with complementary inhibitory functions may prove to be of particular interest for the rapid assessment of the inherent (in)stability of recombinant proteins challenged with the host plant\'s resident proteases, or to retrieve the protein product in a form suitable for further characterization, monitoring and purification ([Michaud, 1998](#b128){ref-type="ref"}; [Benchabane *et al*., 2008](#b137){ref-type="ref"}). Protease inhibitor 'cocktails' composed of inhibitors with different specificities against plant proteases have been devised by several suppliers, and are now commonly used as additives to extraction media for the stabilization of proteins in crude preparations. Various diagnostic inhibitors ([Table 2](#t2){ref-type="table"}) and synthetic peptide substrates for protease assays ([Brunelle and Michaud, 2000](#b138){ref-type="ref"}) are also available as diagnostic tools to characterize proteases and protein hydrolytic processes in crude extracts, and to devise strategies for the protection of proteins to be isolated from heterologous environments ([Benchabane *et al*., 2008](#b137){ref-type="ref"}). Although the testing of different inhibitors is suggested given the general diversity of protease activities in plant crude extracts, small broad‐spectrum inhibitors, such as chymostatin and phenylmethylsulphonyl fluoride, often constitute a good starting point for the stabilization of heterologous proteins *in vitro*, especially in crude extracts prepared from metabolically active tissues, such as stems or green leaves ([Figure 2](#f2){ref-type="fig"}).

###### 

Low‐molecular‐weight protease inhibitors commonly used for protease characterization and protein stabilization in plant extracts[\*](#t2n3){ref-type="fn"}

  Inhibitor             Molecular weight (Da)   Target protease
  --------------------- ----------------------- ---------------------------------------------
  AEBSF                 240                     Serine
  Amastatin             475                     Metallo‐(aminopeptidases)
  Antipain              605                     Serine (trypsin‐like), cysteine
  APMSF                 216                     Serine (trypsin‐like)
  Bestatin              308                     Metallo‐(aminopeptidases)
  Chymostatin           605                     Serine (chymotrypsin‐like), cysteine
  3,4‐DCI               215                     Serine
  Diprotin A            359                     Metallo‐(aminopeptidases)
  Diprotin B            327                     Metallo‐(aminopeptidases)
  E‐64                  357                     Cysteine
  EDTA                  372                     Metallo‐(chelating agent)
  Elastatinal           513                     Serine (elastase‐like)
  Iodoacetamide         185                     Cysteine (may interfere with other enzymes)
  Leupeptin             427                     Serine (trypsin‐like), cysteine
  Pepstatin             686                     Aspartate
  1,10‐Phenanthroline   198                     Metallo‐(chelating agent)
  PMSF                  174                     Serine, cysteine in non‐reducing conditions
  TLCK                  333                     Serine (trypsin‐like)
  TPCK                  352                     Serine (chymotrypsin‐like)
  *Z*‐Phe‐Ala‐CHN~2~    395                     Cysteine

AEBSF, 4‐(2‐aminoethyl)‐benzenesulphonyl fluoride, hydrochloride; APMSF, (4‐Amidinophenyl)‐methanesulfonyl fluoride hydrochloride monohydrate; 3,4‐DCI, 3,4‐dichloro‐isocoumarin; E‐64, [l]{.smallcaps}‐*trans*‐epoxysuccinyl‐leucylamido‐(4‐guanidino) butane; EDTA, ethylenediaminetetraacetic acid; PMSF, phenylmethylsulphonyl fluoride; TLCK, tosyl lysyl chloromethyl ketone; TPCK, tosyl phenylalanyl chloromethyl ketone.

See [Michaud *et al*. (1998](#b32){ref-type="ref"}) for details on stock solutions and working concentrations.

![Stabilization of exogenous proteins in plant crude protein extracts by phenylmethylsulphonyl fluoride (PMSF) and chymostatin (CHY). The example is human fibronectin (hFb) challenged with alfalfa leaf proteases. hFb was first incubated for 10 min at 20 °C with major protease fractions of alfalfa leaf proteases (P1 or P2) in the presence or absence of 0.1 m[m]{.smallcaps} PMSF or 10 µ[m]{.smallcaps} CHY, and then immunodetected using appropriate anti‐hFb polyclonal antibodies. CTL, control extract with no inhibitor added.](PBI-6-633-g002){#f2}

For large‐scale set‐ups, protein protease inhibitors co‐expressed *in planta* with the recombinant protein of interest may represent an effective alternative to commercial low‐molecular‐weight inhibitors ([Rivard *et al*., 2006](#b33){ref-type="ref"}). Protein protection with exogenous protease inhibitors, which relies on expensive and often toxic compounds, appears to be useful for diagnostic purposes or small‐scale production scenarios, but is not applicable to large‐scale production schemes involving the extraction and downstream processing of large biomass samples. By contrast, in‐built companion inhibitors co‐expressed in the host plant are 'included'*de facto* in protein extracts after tissue grinding, and then act as 'mouse traps' against the proteases present to reproduce the protein‐stabilizing effects of exogenous chemical inhibitors ([Benchabane *et al*., 2008](#b137){ref-type="ref"}). Broad‐spectrum protease inhibitors, such as the serine‐type inhibitors tomato CDI and bovine aprotinin, appear to be well suited as such effective companion inhibitors, as illustrated by the strong stabilization of the marker protein neomycin phosphotransferase II released in leaf crude extracts of tomato CDI‐ and bovine aprotinin‐expressing potato plants ([Rivard *et al*., 2006](#b33){ref-type="ref"}). Inhibitors of cysteine proteases, such as cystatins ([Girard *et al*., 2007](#b139){ref-type="ref"}), or hybrid fusion inhibitors integrating dual (or multiple) inhibitory functions active against cysteine, serine and/or aspartate proteases (e.g. [Urwin *et al*., 1998](#b140){ref-type="ref"}; [Brunelle *et al*., 2005](#b141){ref-type="ref"}) also represent interesting candidates, given the general occurrence of serine, cysteine and aspartate protease activities sensitive to such inhibitors in plant crude extracts ([Rivard *et al*., 2006](#b33){ref-type="ref"}, [2007](#b142){ref-type="ref"}; [Goulet *et al*., 2008](#b143){ref-type="ref"}).

Continuous secretion and recovery {#ss16}
---------------------------------

An alternative to protease inhibitors for the avoidance of extraction‐related protein degradation involves skipping this processing step by taking advantage of cellular and tissue secretion processes occurring naturally in plants. In practice, this strategy involves the targeting of recombinant proteins to the extracellular medium using appropriate signal peptides for extracellular secretion, followed by recovery of the extracellular proteins in secreted fluids or culture media. Rhizosecretion and leaf guttation represent two such processes allowing for the non‐destructive secretion and extraction‐free recovery of recombinant proteins ([Komarnytsky *et al*., 2000](#b144){ref-type="ref"}; [Gaume *et al*., 2003](#b88){ref-type="ref"}). Rhizosecretion, notably, has been exploited recently for the heterologous expression of several recombinant proteins, including human alkaline phosphatase ([Gaume *et al*., 2003](#b88){ref-type="ref"}), hepatitis B surface antigen ([Kumar *et al*., 2006](#b145){ref-type="ref"}) and immunoglobulin G antibodies ([Komarnytsky *et al*., 2006](#b127){ref-type="ref"}). This approach is based on the ability of hairy roots to secrete proteins in hydroponic media, which can be recovered easily and used as simple source material for protein enrichment and purification ([Komarnytsky *et al*., 2004](#b90){ref-type="ref"}). Interestingly, rhizosecretion, and hence recombinant protein release, can be significantly boosted by the initiation of hairy roots following treatment with *Agrobacterium rhizogenes* ([Gaume *et al*., 2003](#b88){ref-type="ref"}), thus providing an efficient source of recombinant protein throughout the host plant\'s life.

Plant cell cultures have also been proposed for the continuous secretion of recombinant proteins in culture media ([Hellwig *et al*., 2004](#b86){ref-type="ref"}). Compared with transgenic plant lines, cultured cells offer a high level of containment, and represent a useful tool for designing simple recovery and purification strategies from source media containing low levels of contaminants. However, some recombinant proteins may undergo extensive hydrolysis in culture media, owing to the secretion of proteolytic enzymes by growing cells ([Lee *et al*., 2002](#b146){ref-type="ref"}; [Kwon *et al*., 2003](#b147){ref-type="ref"}; [Schiermeyer *et al*., 2005](#b87){ref-type="ref"}; [Ganapathi *et al*., 2007](#b148){ref-type="ref"}). The extracellular concentration of human granulocyte--macrophage colony‐stimulating factor, for instance, reached a maximum in tobacco cell cultures at the mid‐exponential phase, but then decreased rapidly in the culture medium, together with a dramatic increase in protease activity in the culture medium ([Lee *et al*., 2002](#b146){ref-type="ref"}). In a similar manner, accumulation of the fibrinolytic protease α1 plasminogen activator from *Desmodus rotundus* was dramatically hampered in the culture medium of BY‐2 tobacco cells, presumably as a result of extensive degradation by secreted metalloproteases ([Schiermeyer *et al*., 2005](#b87){ref-type="ref"}). The addition of protein‐stabilizing agents, such as low‐molecular‐weight protease inhibitors or polymers (e.g. gelatin, albumin, polyethylene glycol or polyvinylpyrrolidone), to the culture medium has been proposed to prevent protein loss in plant cell cultures ([Bateman *et al*., 1997](#b149){ref-type="ref"}; [LaCount *et al*., 1997](#b150){ref-type="ref"}; [Tsoi and Doran, 2002](#b151){ref-type="ref"}; [Schiermeyer *et al*., 2005](#b87){ref-type="ref"}; [Soderquist and Lee, 2005](#b152){ref-type="ref"}; [Ganapathi *et al*., 2007](#b148){ref-type="ref"}). The co‐secretion of recombinant protease inhibitors hindering endogenous protease activities along the cell secretory pathway or in the culture medium ([Komarnytsky *et al*., 2006](#b127){ref-type="ref"}; [Kim *et al.*, 2007](#b1000){ref-type="ref"}), or the development of protease‐deficient transgenic plant cells lacking specific, potentially damaging secreted proteases ([Schiermeyer *et al*., 2005](#b87){ref-type="ref"}), could represent interesting alternatives in the future, allowing recombinant proteins secreted in culture media (or natural secretion fluids) to be stabilized *in situ*, without the need to use exogenous protein‐stabilizing chemicals.

Conclusion {#ss17}
==========

In summary, major advances have been made over the last decade to improve the post‐translational stability and accumulation of recombinant proteins in plant systems. The use of tissue‐specific promoters or the addition of subcellular targeting peptide signals to the nascent protein, in particular, have been proven to be useful in increasing the stability of several proteins *in planta*. Complementary approaches relying on protein‐stabilizing fusion partners, companion protease inhibitors or natural secretion processes have also been proposed recently to protect recombinant proteins, either *in planta* during the production stage or *ex planta* at the time of extraction (or secretion). Although a case‐by‐case exploratory assessment involving the testing of different strategies may always remain necessary given the individual characteristics of each protein being expressed or plant platform being exploited, the fine tuning of molecular tools and strategies for recombinant protein stabilization should be made easier in the near future, together with our growing understanding of proteolytic and protein maturation processes in plants. Rapid developments in structural biology and protein engineering should also contribute to the biotechnologist\'s toolbox in forthcoming years, and help us to face the challenge of recalcitrant protein production.
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